西乐葆对雄激素剥夺治疗的前列腺癌患者血清PSA的影响  

The effect of Celecoxib on serum PSA in prostate cancer patients with androgen ablation therapy

作　　者：曹朴[1] 贾瑞鹏[2] 许露伟[2] 薛建新[1] 吴剑平[2] 梁凯[2] 李文成[2] 苏江浩[2] 

机构地区：[1]东南大学临床医学院,江苏南京210009 [2]南京医科大学附属南京第一医院泌尿外科,江苏南京210006

出　　处：《解剖与临床》2010年第4期270-272,共3页Anatomy and Clinics

摘　　要：目的：初步评价选择性环氧合酶-2（COX-2）抑制剂西乐葆对雄激素剥夺治疗（AAT）前列腺癌（Pca）患者血清前列腺特异抗原（PSA）的影响.方法：对33例接受AAT后PSA升高的Pca患者口服西乐葆0.4 g/d,治疗3、6个月时随访血清tPSA、fPSA和f/tPSA,通过比较治疗前后PSA倍增时间（PSADT）、fPSA和f/tPSA的变化,评价西乐葆对AAT患者PSA的影响.结果：西乐葆治疗前,高PSADT 18例（54.5%）,无一例出现tPSA下降;治疗后3、6月时, PSADT延长、血清tPSA下降例数分别为13、10;与治疗前相比,治疗后3、6个月时PSADT、fPSA、f/tPSA差异具有统计学意义（P＜0.05）.结论：选择性COX-2抑制剂西乐葆可降低血清PSA增加速率,对AAT前列腺癌患者产生良好的疗效.Objective： To preliminarily assess the effect of selective COX-2 inhibitor celecoxib on serum PSA in prostate cancer（Pca） patients with androgen ablation therapy （AAT）. Methods：A total of 33 Pea patients with elevated PSA after treatment of AAT received oral celecoxib 0.4g daily. We obtained serum tPSA, tPSA and f/tPSA in 3 and 6 months of the treatment respectively. By comparing the difference of PSA doubling time （ PSADT）, fPSA and f/tPSA during pre- and post-treatment, we evaluated the impact of eelecoxib on PSA in patients undergoing AAT. Results：The number of cases with high PSADT was 18 （54.5%） during pre-treatment of eelecoxib, and there was no decreased tPSA. PSADT prolonged in 3 and 6 months, and the number of cases with decreased tPSA was 13 and 10 respectively. PSADT, fPSA and f/tPSA showed significant difference in 3 and 6 months respectively, compared with pre-treatment. Conclusions：Selective COX-2 inhibitor celeeoxib can reduce the increasing rate of serum PSA and show better effect of therapy on Pea patients with AAT.

关 键 词：环氧合酶-2 前列腺肿瘤 前列腺特异抗原 选择性环氧合酶2抑制剂 雄激素剥夺治疗 

分 类 号：R737.25[医药卫生—肿瘤]